. 2020 Jan;16(1):31–38.

Table 3.

Statins and PPAR Agonists in Primary Sclerosing Cholangitis

Reference	Year	Drug(s)	Study Design	Sample Size	Results
Reference	Year	Drug(s)	Study Design	Sample Size	ALP Levels	Other Endpoints
Mizuno et al⁴⁰	2015	Bezafibrate	Nonrandomized, open-label trial	15	↓	Significant decrease in ALT levels
Mizuno et al³⁹	2010	Bezafibrate	Retrospective cohort	7	↓	Decrease in ALT, GGT, and AST levels
Stokkeland et al³⁶	2019	Statins	Retrospective cohort	404	ND	Significant decrease in liver-related death or transplantation
Lemoinne et al⁴²	2018	Fibrates	Retrospective cohort	20	↓	Significant decrease in levels of ALT but not in GGT, AST, total bilirubin, albumin, prothrombin time, IgG, IgM, or platelet count
Abdalla et al⁴³	2019	Fenofibrate	Nonrandomized, open-label trial	8	↓	Significant decrease in levels of ALT but not in AST, total bilirubin, prothrombin time, or albumin
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltransferase; Ig, immunoglobulin; ND, not determined; PPAR, peroxisome proliferator-activated receptor.